# Pizarra — PT-pseudo_180352970ace (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_180352970ace
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 3.7 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.116 ng/mL²
  - PSA velocity: 1.18 ng/mL/yr
  - Prior PSA: 2.8 ng/mL
  - Prostate volume: 31.97 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7869916 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 3.7 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 32 mL. csPCa 0.79.

Vitals: weight 71 kg, height 183 cm, BMI 21.2, BP 124/82 mmHg, HR 84 bpm. Smoking: Non-smoker.

Chief complaint: Clinical concern stems from a sustained increase in prostate-specific antigen levels coupled with a newly identified high-risk lesion on multiparametric magnetic resonance imaging.

History: At sixty-three years of age, this self-employed carpentry contractor presents with a minimal International Prostate Symptom Score of 5/35, despite an initial workup for hesitancy and frequency two years prior. Prior biopsy bucket: None. He has never wed and resides with his partner, while his grown daughter acts as the designated emergency contact. A strict non-smoker, his daily routine features biweekly tennis matches and a weekly alcohol intake hovering around fourteen units. Medical background remains entirely clear, with no comorbidities or active prescriptions. He denies haematuria, skeletal discomfort, or unaccounted weight reduction, and has arranged for an Arabic interpreter to facilitate his next consultation.

Physical examination: DRE — texture: uniformly smooth; mobility: unrestricted; asymmetry: absent. The gland exhibits no focal irregularities, aligning with a benign digital assessment. Hemodynamic parameters show a blood pressure of 124/82 mmHg and a pulse of 84 beats per minute. Systemic evaluation notes a well-built individual in comfortable repose, featuring unremarkable pulmonary fields and a steady cardiac rhythm upon auscultation.

Patient info: self-employed contractor (carpentry); Never married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 14 units / week; exercise Tennis 2x/week; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.87 +/- 0.12   (95% CI 0.57-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.06  (few labelled cases resemble this one)
  - 8.2 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=3.7, age=63.0, psad=0.116, dre_ord=0.0, vol=31.97, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5, PSA=3.7, csPCa probability=0.79) and failed to incorporate the PSA velocity (1.18 ng/mL/yr), the PSA density (0.116 ng/mL²), and the prior biopsy status (None).
WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability, but it ignores the potential for overdiagnosis given the high csPCa probability (0.79) and the fact that the prior biopsy was None. The prior's high confidence interval suggests the decision is robust, but this ignores the uncertainty inherent in the statistical model when key longitudinal data (PSA velocity) is missing.
WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - trend / velocity beyond the headline value
laboratory panel - full panel
previous GP / urology notes
family-history anamnesis
GUIDELINE ANCHOR
The guideline suggests that a PI-RADS $\ge 3$ mandates biopsy, and the risk-adapted matrix table involving PSA density and PSA levels may guide the decision.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Prostate Multiparametric MRI | Institution: Catharina Ziekenhuis, Eindhoven | Date: 15 January 2025
PI-RADS 5 lesion in the right mid peripheral zone. Prostate volume 31.97 mL. PSA density 0.116 ng/mL/mL. csPCa predicted probability 0.7869916.

get_psa_trend
[{"date": "Oct 2022", "val": 1.6}, {"date": "Jul 2023", "val": 2.1}, {"date": "Apr 2024", "val": 2.8}, {"date": "Jan 2025", "val": 3.7}]

get_lab_results
PSA: 3.7 ng/mL (13 Dec 2024). %Free PSA: 17% (13 Dec 2024).

get_previous_notes
[{"date": "24 Jan 2024", "author": "Dr. K. Bakker (GP)", "text": "During a standard check-in, laboratory results placed the prostate-specific antigen at 2.8 ng/mL, highlighting a consistent climb from earlier values. No bothersome voiding complaints or constitutional symptoms were noted. Urology consultation was arranged to investigate the upward trend."}, {"date": "29 Jan 2023", "author": "Dr. K. Bakker (GP)", "text": "A scheduled assessment noted a prostate-specific antigen reading of 1.8 ng/mL, edging past prior reference points. Occasional daytime urinary frequency was reported, though obstructive features remained absent."}]

NOT RETRIEVED
The family-history anamnesis was not retrieved, which could potentially influence the risk stratification.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right mid peripheral zone.
- PSA trend: Rising from 1.6 ng/mL (Oct 2022) to 3.7 ng/mL (Jan 2025), with a velocity of 1.18 ng/mL/yr between the last two measurements.
- Guideline criterion: PI-RADS $\ge 3$ mandates biopsy.

AGAINST sampling this patient now:
- MRI report: Lesion is described as a discrete 12 mm focus, but the report does not explicitly state if it is new or larger compared to a previous study.

WHERE THIS LEANS
The evidence strongly supports proceeding with a biopsy due to the high-risk PI-RADS 5 finding and the documented rising PSA velocity, confirming the statistical prior's suggestion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision is to proceed with biopsy because the PI-RADS score of 5 is decisive, as per the guideline criterion for biopsy when PI-RADS is 3 or higher. This finding was supported by the retrieved mpMRI report, which identified a PI-RADS 5 lesion. The rising PSA trend, moving from 1.6 ng/mL to 3.7 ng/mL, further supports the need for tissue sampling. The statistical prior and the guideline criterion converged on this recommendation.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
